Progress in Neuro-Psychopharmacology and Biological Psychiatry, Journal Year: 2025, Volume and Issue: unknown, P. 111354 - 111354
Published: April 1, 2025
Language: Английский
Life, Journal Year: 2024, Volume and Issue: 14(5), P. 559 - 559
Published: April 26, 2024
The gastrointestinal tract is home to trillions of diverse microorganisms collectively known as the gut microbiota, which play a pivotal role in breaking down undigested foods, such dietary fibers. Through fermentation these food components, short-chain fatty acids (SCFAs) acetate, propionate, and butyrate are produced, offering numerous health benefits host. production absorption SCFAs occur through various mechanisms within human intestine, contingent upon types fibers reaching specific engaged fermentation. Medical literature extensively documents supplementation SCFAs, particularly butyrate, treatment gastrointestinal, metabolic, cardiovascular, gut-brain-related disorders. This review seeks provide an overview dynamics involved gut. Additionally, it will focus on roles promoting metabolic health, well their current therapeutic implications.
Language: Английский
Citations
51
Clinical Microbiology Reviews, Journal Year: 2024, Volume and Issue: 37(2)
Published: May 8, 2024
SUMMARYGiven the importance of gut microbial homeostasis in maintaining health, there has been considerable interest developing innovative therapeutic strategies for restoring microbiota. One such approach, fecal microbiota transplantation (FMT), is main "whole microbiome replacement" strategy and integrated into clinical practice guidelines treating recurrent
Language: Английский
Citations
45
Antibiotics, Journal Year: 2024, Volume and Issue: 13(5), P. 436 - 436
Published: May 12, 2024
Clostridioides difficile infection (CDI) is an intestinal that causes morbidity and mortality places significant burden cost on the healthcare system, especially in recurrent cases. Antibiotic overuse well recognized as leading cause of CDI high-risk patients, studies have demonstrated even short-term antibiotic exposure can a large persistent disturbance to human colonic microbiota. The recovery sustainability gut microbiome after dysbiosis been associated with fewer recurrences. Fecal microbiota transplantation (FMT) refers procedure which donor stool processed transplanted patient CDI. It has historically used patients pseudomembranous colitis before discovery difficile. More recent research supports use FMT part standard therapy This article will be in-depth review five therapeutic products are either under investigation or currently commercially available: Rebyota (fecal microbiota, live-jslm, formerly RBX2660), Vowst spores, live-brpk, SER109), VE303, CP101, RBX7455. Included this comparison products’ composition dosage forms, available safety efficacy data, investigational status.
Language: Английский
Citations
8
Gastroenterology, Journal Year: 2024, Volume and Issue: 167(5), P. 885 - 902
Published: May 14, 2024
Language: Английский
Citations
5
Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)
Published: Nov. 5, 2024
Faecal/intestinal microbiota transplant (FMT/IMT) is an efficacious treatment option for recurrent Clostridioides difficile infection, which has prompted substantial interest in FMT's potential role the management of a much broader range diseases associated with gut microbiome. Despite its promise, success rates FMT these other settings have been variable. This review critically evaluates current evidence on impact clinical, biological, and procedural factors upon therapeutic efficacy FMT, identifies areas that remain nebulous. Due to some factors, optimal approach remains unclear; example, preferred timing administration heavily antibiotic-exposed hematopoietic cell recipient not standardized, arguments can be made alternate directions. We explore how may more informed selection donors, matching donors recipients, aspects clinical care recipients. includes consideration microbiome composition functionality strategically inform donor criteria. Furthermore, we most productive advances within space are those where translational outcomes assessed together, this model used productively recent years better understand contribution human disease, start process toward development targeted therapeutics.
Language: Английский
Citations
5
Annals of Pharmacotherapy, Journal Year: 2024, Volume and Issue: unknown
Published: March 28, 2024
To review the efficacy, safety, and role of live biotherapeutic products (LBPs) in prevention recurrent
Language: Английский
Citations
4
Current Opinion in Gastroenterology, Journal Year: 2024, Volume and Issue: 40(4), P. 258 - 267
Published: April 10, 2024
The role of the microbiome and dysbiosis is increasingly recognized in pathogenesis inflammatory bowel disease (IBD). Intestinal microbiota transplant (IMT), previously termed fecal has demonstrated efficacy restoring a healthy promoting gut health recurrent Clostridioides difficile infection. Several randomized trials (RCTs) highlighted IMT's potential treating ulcerative colitis, while smaller studies reported on its application managing Crohn's pouchitis.
Language: Английский
Citations
4
World Journal of Clinical Cases, Journal Year: 2024, Volume and Issue: 12(24), P. 5468 - 5472
Published: July 10, 2024
The management of refractory ulcerative colitis (UC) and acute severe UC (ASUC) is challenging due to the lack standardized approaches in cases resistant multiple treatments. In this editorial, I investigate efficacy safety Janus kinase inhibitors, particularly upadacitinib tofacitinib, controlling disease. highlight a notable case report by Xu et al , which explores patient with primary nonresponse two classes biologics fecal microbiota transplants who exhibited remarkable response upadacitinib. Furthermore, discuss use tofacitinib ASUC, either as monotherapy or combination biologics, has shown promising rates. Additionally, emerging evidence ASUC presented. Overall, these emphasize complex nature managing potential small-molecule therapies achieve remission. Further research needed refine treatment strategies for patients treatment-resistant UC.
Language: Английский
Citations
4
Gut Microbes, Journal Year: 2024, Volume and Issue: 16(1)
Published: Sept. 3, 2024
Clostridioides difficile is a major nosocomial pathogen, causing significant morbidity and mortality worldwide. Antibiotic usage, risk factor for infection (CDI), disrupts the gut microbiota, allowing C. to proliferate cause infection, can often lead recurrent CDI (rCDI). Fecal microbiota transplantation (FMT) live biotherapeutic products (LBPs) have emerged as effective treatments rCDI aim restore colonization resistance provided by healthy microbiota. However, much still unknown about mechanisms mediating their success. Bile acids, extensively modified microbes, affect difficile's germination, growth, toxin production while also shaping influencing host immune responses. Additionally, microbial interactions, such nutrient competition cross-feeding, contribute against may success of microbiota-focused therapeutics. acids well other mediated interactions could implications diseases being treated with This review focuses on intricate interplay between bile acid modifications, ecology, responses focus difficile, hoping shed light how move forward development new therapeutic strategies combat intestinal diseases.
Language: Английский
Citations
4
World Journal of Gastroenterology, Journal Year: 2025, Volume and Issue: 31(6)
Published: Jan. 10, 2025
Inflammatory bowel diseases (IBDs) are classified into two distinct types based on the area and severity of inflammation: Crohn's disease (CD) ulcerative colitis. In CD, gut bacteria can infiltrate mesenteric fat, causing expansion known as creeping which may limit bacterial spread inflammation but promote fibrosis. The composition varies depending whether colon or ileum is affected. Fecal microbiota transplantation (FMT) transfers feces from a healthy donor to restore balance, often used in IBD patients reduce mucosal repair. use FMT for CD remains uncertain, with insufficient evidence fully endorse it definitive treatment. While some studies suggest improve symptoms, questions about duration these improvements need repeated treatments persist. There pressing methods that provide long-term benefits, highlighted by Wu et al's research.
Language: Английский
Citations
0